Breast Density and Breast Cancer Risk: Understanding of Biology and Risk

Associations of Oral Contraceptives with Mammographic Breast Density in Premenopausal Women

BACKGROUND

We investigated the associations of oral contraceptives (OC) with percent breast density (PD), absolute dense area (DA), nondense area (NDA), and a novel image intensity variation (V) measure in premenopausal women.

METHODS

This study included 1,233 controls from a nested case-control study within Nurses' Health Study II cohort. Information on OCs was collected in 1989 and updated biennially. OC use was defined from the questionnaire closest to the mammogram date. PD, DA, and NDA were measured from digitized film mammograms using a computer-assisted thresholding technique; the V measure was obtained with a previously developed algorithm measuring the SD of pixel values in the eroded breast region. Generalized linear regression was used to assess associations between OCs and density measures (square root-transformed PD, DA, and NDA, and -untransformed V).

RESULTS

OC use was not associated with PD [current vs. never: β = -0.06; 95% confidence interval (CI), -0.37-0.24; past vs. never: β = 0.10; 95% CI, -0.09-0.29], DA (current vs. never: β = -0.20; 95% CI -0.59-0.18; past vs. never: β = 0.13; 95% CI, -0.12-0.39), and NDA (current vs. never: β = -0.19; 95% CI, -0.56-0.18; past vs. never: β = -0.01; 95% CI, -0.28-0.25). Women with younger age at initiation had significantly greater V-measure (<20 years vs. never: β = 26.88; 95% CI, 3.18-50.58; 20-24 years vs. never: β = 20.23; 95% CI, -4.24-44.71; 25-29 years vs. never: β = 2.61; 95% CI -29.00-34.23; ≥30 years vs. never: β = 0.28; 95% CI, -34.16-34.72, P _trend = 0.03).

CONCLUSIONS

Our findings suggest that an earlier age at first OC use was associated with significantly greater V.

IMPACT

These findings could guide decisions about the age for OC initiation.

Spatial Correlation and Breast Cancer Risk

We present a novel method for evaluating local spatial correlation structure in two-dimensional (2D) mammograms and evaluate its capability for risk prediction as one possible application. Two matched case-control studies were analyzed. Study 1 included women (N = 588 pairs) with mammograms acquired with either Hologic Selenia full field digital mammography (FFDM) units or Hologic Dimensions digital breast tomosynthesis units. Study 2 included women (N =180 pairs) with mammograms acquired with a General Electric Senographe 2000D FFDM unit. Matching variables included age, HRT usage/duration, screening history, and mammography unit. Local autocorrelation functions were determined with Fourier analysis and compared with a template defined as a 2D double-sided exponential function with one spatial extent parameter: n = 4, 12, 24, 50, 74, 100, and 124, where (n+1)×(n+1) is the area of the local spatial extent measured in pixels. The difference between the local correlation and template was gauged within an adjustable parameter kernel and summarized, producing two measures: the mean (m_n+1)_, and standard deviation (s_n+1). Both adjustable parameters were varied in Study 1. Select measures that produced significant associations with breast cancer were translated to Study 2. Breast cancer associations were evaluated with conditional logistic regression, adjusted for body mass index and ethnicity. Odds ratios (ORs) were estimated as per standard deviation increment with 95% confidence intervals (CIs). Two measures were selected for breast cancer association analysis in Study 1: m₇₅ and s₂₅. Both measures revealed significant associations with breast cancer: OR = 1.45 (1.23, 1.66) for m₇₅ and OR = 1.30 (1.14, 1.49) for s_25. When translating to Study 2, these measures also revealed significant associations: OR = 1.49 (1.12, 1.96) for m₇₅ and OR = 1.34 (1.06, 1.69) for s₂₅. Novel correlation metrics presented in this work produced significant associations with breast cancer risk. This approach is general and may have applications beyond mammography.

Generalized breast density metrics

Mammograms represent data that can inform future risk of breast cancer. Data from two case-control study populations were analyzed. Population 1 included women (N  =  180 age matched case-control pairs) with mammograms acquired with one indirect x-ray conversion mammography unit. Population 2 included women (N  =  319 age matched case-control pairs) with mammograms acquired from 6 direct x-ray conversion units. The Fourier domain was decomposed into n concentric rings (radial spatial frequency bands). The power in each ring was summarized giving a set of measures. We investigated images in raw, for presentation (processed) and calibrated representations and made comparison with the percentage of breast density (BD) determined with the operator assisted Cumulus method. Breast cancer associations were evaluated with conditional logistic regression, adjusted for body mass index and ethnicity. Odds ratios (ORs), per standard deviation increase derived from the respective breast density distributions and 95% confidence intervals (CIs) were estimated. A measure from a lower radial frequency ring, corresponding 0.083-0.166 cycles mm^-1 and BD had significant associations with risk in both populations. In Population 1, the Fourier measure produced significant associations in each representation: OR  =  1.76 (1.33, 2.32) for raw; OR  =  1.43 (1.09, 1.87) for processed; and OR  =  1.68 (1.26, 2.25) for calibrated. BD also provided significant associations in Population 1: OR  =  1.72 (1.27, 2.33). In Population 2, the Fourier measure produced significant associations for each representation as well: OR  =  1.47 (1.19, 1.80) for raw; OR  =  1.38 (1.15, 1.67) for processed; and OR  =  1.42 (1.15, 1.75) for calibrated. BD provided significant associations in Population 2: OR  =  1.43 (1.17, 1.76). Other coincident spectral regions were also predictive of case-control status. In sum, generalized breast density measures were significantly associated with breast cancer in both FFDM technologies.

Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies

Increased mammographic density (MD) has been shown beyond doubt to be a marker for increased breast cancer risk, though the underpinning pathobiology is yet to be fully elucidated. Estrogenic activity exerts a strong influence over MD, which consequently has been observed to change predictably in response to tamoxifen anti-estrogen therapy, although results for other selective estrogen receptor modulators and aromatase inhibitors are less consistent. In both primary and secondary prevention settings, tamoxifen-associated MD changes correlate with successful modulation of risk or outcome, particularly among pre-menopausal women; an observation that supports the potential use of MD change as a surrogate marker where short-term MD changes reflect longer-term anti-estrogen efficacy. Here we summarize endocrine therapy-induced MD changes and attendant outcomes and discuss both the need for outcome surrogates in such therapy, as well as make a case for MD as such a monitoring marker. We then discuss the process and steps required to validate and introduce MD into practice as a predictor or surrogate for endocrine therapy efficacy in preventive and adjuvant breast cancer treatment settings.

Dense and nondense mammographic area and risk of breast cancer by age and tumor characteristics

BACKGROUND

Mammographic density (MD) is a strong breast cancer risk factor. We previously reported associations of percent mammographic density (PMD) with larger and node-positive tumors across all ages, and estrogen receptor (ER)-negative status among women ages <55 years. To provide insight into these associations, we examined the components of PMD [dense area (DA) and nondense area (NDA)] with breast cancer subtypes.

METHODS

Data were pooled from six studies including 4,095 breast cancers and 8,558 controls. DA and NDA were assessed from digitized film-screen mammograms and standardized across studies. Breast cancer odds by density phenotypes and age according to histopathologic characteristics and receptor status were calculated using polytomous logistic regression.

RESULTS

DA was associated with increased breast cancer risk [OR for quartiles: 0.65, 1.00 (Ref), 1.22, 1.55; P(trend) <0.001] and NDA was associated with decreased risk [ORs for quartiles: 1.39, 1.00 (Ref), 0.88, 0.72; P(trend) <0.001] across all ages and invasive tumor characteristics. There were significant trends in the magnitude of associations of both DA and NDA with breast cancer by increasing tumor size (P(trend) < 0.001) but no differences by nodal status. Among women <55 years, DA was more strongly associated with increased risk of ER(+) versus ER(-) tumors (P(het) = 0.02), while NDA was more strongly associated with decreased risk of ER(-) versus ER(+) tumors (P(het) = 0.03).

CONCLUSIONS

DA and NDA have differential associations with ER(+) versus ER(-) tumors that vary by age.

IMPACT

DA and NDA are important to consider when developing age- and subtype-specific risk models.